[Event Report] The Second Meeting of Working Group 2 Under the Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) (August 18, 2020)
date : 9/3/2020
Tags: AMR
Nikkei Inc. and AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) jointly held the Second Meeting of Working Group 2 Under the Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC).
Working groups (WG) were established under the Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) in order to discuss the state of the antimicrobial market.
At this second meeting of WG2, participants exchanged opinions on the size of pull incentives needed in Japan, and the type of data needed to justify incentives of that size.
On the basis of WG discussions, participants agreed to join the third sub-committee on AMR and continue to work hard toward the eventual formulation of a concrete proposal on ways to incentivize antimicrobial R&D in the future.
In light of the situation with novel coronavirus, this meeting was carried out primarily online. On-site participants were encouraged to keep a safe physical distance from each other.
■Overview
Date and time: Tuesday, August 18, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Discussion
WG2 Members (alphabetical order by last name):
Yusuke Ariyoshi (Director, Healthcare Policy, Government Affairs Dept., Shionogi & Co., Ltd.)
Yoshiaki Gu (Chief, Information and Education Division, AMR Clinical Reference Center, National Center for Global Health and Medicine)
Yuri Miura (Senior Industry Policy Specialist, Public and Industrial Policy, Health Policy, MSD K.K.)
Kazumasa Oguro (Professor, Faculty of Economics, Hosei University)
Motoyuki Sugai (Director, Antimicrobial Resistance Research Center, National Institute of Infectious Diseases)
Yoshisaburo Takahashi (General Manager, Vaccine/Infections Dept., Meiji Seika Pharma Co., Ltd.)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Akira Yuasa (Senior Manager, HTA/HEOR, Corporate Affairs, Health & Value, Pfizer Japan Inc.)
Moderator:
Yui Kohno (AMR Alliance Japan Secretariat/Associate, HGPI)
Secretariat (alphabetical order by last name):
Yuiko Kondo (AMR Alliance Japan Secretariat/Senior Associate, HGPI)
Matt McEnany (AMR Alliance Japan Secretariat/Senior Manager, HGPI)
Tomohito Shibata (AMR Alliance Japan Secretariat/Senior Associate, HGPI)
Miki Shirakawa (The Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) Project, Nikkei Inc.)
Chiaki Toma (The Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) Project, Nikkei Inc.)
Mio Wakasa (The Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) Project, Nikkei Inc.)
■Related events held as part of the “The Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC)” project in and after FY2019 (chronological order)
January 22, 2020 The First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC)
July 17, 2020 The Third Meeting of Working Group 1 Under the Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC)
Top Research & Recommendations Posts
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Policy Recommendations] The Women’s Health Promotion Project “Policy proposal for Promotion of Menopausal Women’s Health as a Social Issue to be Considered by Industry, Government, Academia and the Private Sector” (July 31, 2024)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Reserch Report] Antimicrobial Resistance (AMR) Measures in Sweden (November 21, 2024)
Featured Posts
-
2024-11-25
[Registration Open] (Webinar) The 130th HGPI Seminar “Marking a Decade of the Act on Medical Care for Patients With Intractable Diseases: Connecting Intractable Diseases and Society From the Perspective of a Media Professional and Family Member” (January 28, 2025)
-
2024-11-29
[Registration Open] (Webinar) The 129th HGPI Seminar “The Connection Between Planetary Environment and Human Health as Seen Through the JECS and Future Expectations” (December 23, 2024)
-
2024-12-09
[Policy Recommendations] Integrating Climate and Health for a Sustainable Society: Incorporating a Planetary Health Perspective into Nationally Determined Contributions (NDCs)(December 9, 2024)
-
2024-12-12
[HGPI Policy Column] (No. 51) From the Planetary Health Project “Part 11: Efforts Toward Achieving Carbon Neutrality in Japan’s Pharmaceutical Industry”
-
2024-12-18
[Policy Recommendations] Policy Recommendations on Strengthening CKD Strategies for Workers: The Importance of Providing Early Detection, Intervention, and Support Through Screenings and Medical Visits (October 28, 2024)